As Personalized Medicine Beckons, Orchid s SNP Business Takes a Back Seat | GenomeWeb

NEW YORK, Oct. 10 - Orchid Biosciences will gradually pull out of the SNP-genotyping business as it moves closer to launching its GeneShield personalized-medicine platform, George Poste, the company's new chairman, said today.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.